Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Rheumatology
•
Rheumatoid Arthritis
•
General Rheumatology
•
Allergy & Immunology
•
Pulmonology
•
Asthma
Are there concerns with combining anti-IL5 biologics (mepolizumab or benralizumab) for severe asthma with other biologics for RA (e.g. TNFi)?
Related Questions
Would you use the pneumococcal conjugate-21 vaccine (Capvaxive) instead of the conjugate-20 (Prevnar-20) for routine vaccinations in immunosuppressed patients?
What is your approach to differentiating RA-ILD from medication toxicity (I.e. from methotrexate)?
Can Xolair (omalizumab) be safely used in combination with biologics for patients with rheumatic disease?
Is it necessary to prescribe a steroid taper after two weeks of high-dose prednisone (60 mg daily)?
In a patient with low titer +anti-SAE antibody and known ILD, but no other clinical features of dermatomyositis, how would you approach further testing or would you treat the patient as dermatomyositis associated ILD?
How long do you recommend that a patient wear a mask when resuming biologic infusions following a recent upper respiratory infection?
How do you approach managing nausea and GI side effects when initiating methotrexate?
How do you approach use of DMARDs and/or biologics for inflammatory arthritis in patients with a history of seizure disorder on anti-epileptic medications?
What approaches can we take to initiate therapy and improve survival rates in patients with HLH?
Which patient characteristics or scenarios drive you to choose tezepelumab over dupilumab for asthma?
